Session Information
Session Type: Abstract Submissions (ACR)
Background/Purpose:
The efficacy of anti-TNF in the management of psoriatic arthritis (PsA) has been demonstrated in numerous controlled clinical trials. Longitudinal observational studies assessing the real-world effectiveness of anti-TNF agents are essential in order to demonstrate the true benefits. The objective of this study was to assess in Canadian routine clinical practice the 12-month outcomes in patients with PsA treated with infliximab.
Methods:
Biologic Treatment Registry Across Canada (BioTRAC) is an ongoing, prospective registry of patients initiating treatment for RA, AS, or PsA with infliximab or golimumab as first biologics or after having been treated with a biologic for less than six months. People with PsA treated with infliximab who were enrolled between 2005 and 2012 were included in this analysis. Descriptive statistics were produced for clinical outcome measures and patient reported outcomes at baseline and six or twelve months of treatment. Within-group changes were assessed for statistical significance with the paired-samples Student’s t-test.
Results:
A total of 92 PsA patients were included in the analysis. Mean (SD) age of the patient cohort was 48.7 (9.9) years and mean (SD) duration since diagnosis was 6.8 (9.1) years. The majority of patients were male (52.2%). Upon six months of treatment, statistically significant (P<0.05) and clinical meaningful improvements were observed in all parameters analyzed, which were sustained over 12 months of treatment. Mean (SD) patient parameters at baseline and 12 months of treatment were: PASI: 3.3 (5.6) vs. 1.3 (2.2), P=0.009; DAS28-CRP: 4.0 (1.3) vs. 2.8 (1.3), P=0.002; C-reactive protein (CRP): 13.0 (18.9) vs. 8.2 (12.5) mg/L, P=0.196; erythrocyte sedimentation rate (ESR): 21.4 (22.7) vs. 12.9 (15.4) mm/hr, P=0.171; morning stiffness: 58.1 (45.3) vs. 40.0 (43.1) min, P=0.020; tender joint count (TJC28): 5.9 (5.3) vs. 3.0 (4.7), P=0.001; swollen joint count (SJC28): 4.0 (3.8) vs. 1.9 (3.7), P=0.001; health assessment questionnaire (HAQ-DI): 1.15 (0.66) vs. 0.86 (0.77), P=0.001; patient global assessment of disease activity (PtGA): 5.0 (2.8) vs. 3.5 (2.9) cm, P=0.005; physician global assessment of disease activity (MDGA): 5.8 (2.2) cm vs. 2.6 (2.3), P<0.001; pain: 46.4 (25.6) vs. 33.1 (28.5) mm, P=0.013.
Conclusion:
The results of this Canadian longitudinal observational study have shown that a significant burden of illness is observed at initiation of infliximab in PsA patients in routine clinical practice. Treatment with infliximab was effective in reducing symptom severity and improving outcomes in patients with PsA over 12 months.
Disclosure:
P. Rahman,
Amgen, Abbott, BMS, Merck, Pfizer, Janssen, Hoffman-La Roche, UCB, Novartis, Sanofi-Aventis,
5,
Amgen, Abbott, BMS, Merck, Pfizer, Janssen, Hoffman-La Roche, UCB, Novartis, Sanofi-Aventis,
9;
M. M. Khraishi,
Hoffman-La Roche Canada, Amgen and Pfizer Canada, and Abbott Canada.,
2;
W. Bensen,
None;
J. T. Kelsall,
None;
B. D. Hanna,
None;
C. Watts,
None;
E. Rampakakis,
None;
J. S. Sampalis,
None;
M. Shawi,
Janssen Canada,
3;
S. M. Otawa,
Janssen Canada,
3;
A. J. Lehman,
Janssen Canada,
3.
« Back to 2013 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/real-world-effectiveness-of-infliximab-in-the-treatment-of-psoriatic-arthritis-over-12-months-the-canadian-experience/